サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791825

連続バイオプロセスの世界市場

Continuous Bioprocessing

出版日
ページ情報
英文 553 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
連続バイオプロセスの世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 553 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

連続バイオプロセスの世界市場は2030年までに7億4,460万米ドルに達する見込み

2024年に2億5,100万米ドルと推定される連続バイオプロセスの世界市場は、2030年には7億4,460万米ドルに達し、分析期間2024-2030年のCAGRは19.9%で成長すると予測されます。本レポートで分析したセグメントの1つであるバイオプロセス機器は、CAGR23.3％を記録し、分析期間終了時には5億1,430万米ドルに達すると予測されます。バイオプロセス消耗品セグメントの成長率は、分析期間中CAGR 14.0％と推定されます。

米国市場は6,840万米ドルと推定、中国はCAGR27.4%で成長予測

米国の連続バイオプロセス市場は、2024年には6,840万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億8,010万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは27.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、それぞれ分析期間中に15.4%と18.0%のCAGRで成長すると予測されています。欧州では、ドイツがCAGR約16.7%で成長すると予測されています。

世界の連続バイオプロセス市場- 技術革新と主要成長促進要因

なぜ連続バイオプロセスがバイオ医薬品製造に変革をもたらすのか？

連続バイオプロセスは、バイオ医薬品製造の展望を再定義し、従来のバッチ処理に代わる、より効率的で費用対効果が高く、スケーラブルな代替手段を提供しています。モノクローナル抗体、ワクチン、細胞・遺伝子治療を含む生物製剤の需要が増加し続ける中、バイオ医薬品業界は、高い製品品質を維持しながら製造プロセスを最適化する必要に迫られています。従来のバッチ処理では、段階的に製造工程を分けるため、サイクルタイムが長くなり、運用コストが増大し、製品品質にばらつきが生じることが少なくありませんでした。これに対して連続バイオプロセスは、リアルタイムで中断のない生産を可能にし、一貫性の向上、歩留まりの向上、生産時間の短縮を可能にします。

連続バイオプロセス採用の主な原動力のひとつは、プロセス強化とオペレーション効率への注目が高まっていることです。連続的な上流と下流の処理技術を統合することにより、メーカーはバイオ製造施設のフットプリントを大幅に削減し、資源利用を最適化し、廃棄物の発生を最小限に抑えることができます。さらに、FDAやEMAなどの規制機関は、工程管理を強化し、拡張性を向上させ、確実な製品品質を確保する可能性があるとして、連続製造への移行をますます支持するようになっています。個別化医療や迅速なワクチン開発に向けて業界が動き出す中、連続バイオプロセスは、厳格な規制遵守を維持しながら医薬品製造を加速させる、画期的なアプローチとして台頭してきています。

技術の進歩はどのように連続バイオプロセスを進化させているのでしょうか？

技術の進歩は、連続バイオプロセスの急速な普及の中核であり、より高度な自動化、リアルタイムのモニタリング、プロセスコントロールの強化を可能にします。灌流バイオリアクター、シングルユーステクノロジー、高度なクロマトグラフィーシステムの統合は、連続処理を従来のバッチ法に代わる実行可能な方法とする上で重要な役割を果たしています。特に灌流バイオリアクターは、細胞の生存率と生産性を維持しながら培養液を常に更新することを可能にし、プロセスの中断を減らして生物製剤の高い収率を保証します。

プロセス分析技術とリアルタイム・モニタリング・システムの導入は、連続バイオプロセスをさらに革新しました。pH、溶存酸素、栄養レベル、細胞密度などの重要なプロセスパラメーターを継続的にモニターするために、高度なセンサー技術、AI主導のデータ分析、デジタルツインが活用されています。このリアルタイムのデータ収集により、予測的なプロセス制御、逸脱の早期発見、即時の是正措置が可能になり、バッチ不良や製品の不一致のリスクが低減されます。さらに、シングルユース・バイオプロセシング・システムは、より高い柔軟性、コンタミネーションリスクの低減、資本支出の削減を可能にし、連続製造において支持を集めています。バイオプロセスの自動化、機械学習、デジタルバイオマニュファクチャリングの融合が進むにつれて、連続処理は完全に統合された、高効率でコスト効率の高い生産モデルへと急速に進化しています。

連続バイオプロセスの主な業界アプリケーションは何ですか？

連続バイオプロセスは、効率性、スケーラビリティ、プロセスの信頼性が最重要視されるバイオ医薬品業界の複数の分野で広く採用されています。主な応用分野の一つは、モノクローナル抗体の製造です。安定した細胞培養を維持し、高品質の生物製剤を継続的に採取する能力により、生産効率は著しく向上しています。標的治療薬やバイオシミラーの需要が高まる中、連続処理によって、バイオ製薬会社は、高い純度と効力を維持しながら、モノクローナル抗体を低コストで製造できるようになっています。

連続バイオプロセスのもう一つの主要な用途はワクチン製造であり、特にパンデミック対策として迅速な対応プラットフォームの必要性が高まっています。従来のワクチン製造は、スケールアップの制限や長い製造サイクルに関連する課題にしばしば直面しますが、連続プロセスにより、緊急時の需要に効率的に対応できる、より迅速で適応性の高い製造が可能になります。同様に、細胞治療や遺伝子治療の製造では、ウイルスベクター製造の強化、細胞拡大技術の向上、個別化治療の市場投入までの時間短縮を目的とした連続バイオプロセスアプローチの活用が進んでいます。生物製剤の受託製造分野でも、連続生産ソリューションに対する需要が急増しています。これは、企業が進化する規制基準へのコンプライアンスを確保しながら、大規模な生物製剤製造を最適化しようとしているためです。

連続バイオプロセス市場の成長を促進する要因とは？

連続バイオプロセス市場の成長は、生物製剤に対する世界の需要の増加、バイオプロセス技術の進歩、連続製造に対する規制当局のサポート、コスト効率の高い製造ソリューションの必要性など、いくつかの要因によってもたらされます。バイオシミラーや個別化医療の拡大に伴い、製薬企業はさまざまな生産需要に対応できる柔軟で拡張性の高い製造プロセスの開発を迫られています。連続バイオプロセスは、生産性の向上、サイクルタイムの短縮、運用コストの削減を可能にし、長期的なプロセス効率を求めるバイオ製薬企業にとって魅力的な投資となります。

自動化、AI主導の分析、リアルタイムのプロセス制御など、インダストリー4.0技術の採用が進み、連続バイオプロセスシステムの精度と信頼性が向上していることも重要な推進力となっています。また、持続可能なバイオマニュファクチャリングへの注目の高まりも、連続処理によってエネルギー消費を最小限に抑え、廃棄物の発生を減らし、全体的な資源利用を向上させることから、重要な役割を果たしています。さらに、バイオ医薬品業界では、モジュール式やシングルユースのバイオプロセス設備へのシフトが、連続製造の採用を加速させており、企業にはより大きな運用の柔軟性とコスト削減がもたらされています。高速で高効率なバイオ医薬品製造のニーズが高まり続ける中、連続バイオプロセスはバイオ医薬品製造の未来を担う存在となり、より迅速な医薬品開発、より高い品質基準、救命治療へのアクセスの向上を世界中で実現します。

セグメント

製品タイプ（バイオプロセス機器、バイオプロセス消耗品）;事業規模（商業運営、研究開発運営）;プロセスタイプ（下流バイオプロセス、上流バイオプロセス）;用途（モノクローナル抗体用途、ワクチン用途、細胞・遺伝子治療用途、その他用途）;最終用途（製薬・バイオテクノロジー企業最終用途、CMO・CRO最終用途、研究・学術機関最終用途）

調査対象企業の例

  • 3M Company
  • AGC Biologics
  • Biogen Inc.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Corning Incorporated
  • Danaher Corporation
  • Entegris, Inc.
  • Enzene Biosciences Ltd.
  • Eppendorf SE
  • FUJIFILM Diosynth Biotechnologies
  • Meissner Filtration Products, Inc.
  • Merck KGaA
  • Novasep
  • Repligen Corporation
  • Sanofi Genzyme
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • UCB Pharma
  • WuXi Biologics

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオトランスクリプト、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中のドメインエキスパートからキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30219

Global Continuous Bioprocessing Market to Reach US$744.6 Million by 2030

The global market for Continuous Bioprocessing estimated at US$251.0 Million in the year 2024, is expected to reach US$744.6 Million by 2030, growing at a CAGR of 19.9% over the analysis period 2024-2030. Bioprocessing Instruments, one of the segments analyzed in the report, is expected to record a 23.3% CAGR and reach US$514.3 Million by the end of the analysis period. Growth in the Bioprocessing Consumables segment is estimated at 14.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$68.4 Million While China is Forecast to Grow at 27.4% CAGR

The Continuous Bioprocessing market in the U.S. is estimated at US$68.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$180.1 Million by the year 2030 trailing a CAGR of 27.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.4% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.7% CAGR.

Global Continuous Bioprocessing Market - Innovations & Key Growth Drivers

Why is Continuous Bioprocessing Transforming Biopharmaceutical Manufacturing?

Continuous bioprocessing is redefining the landscape of biopharmaceutical manufacturing, offering a more efficient, cost-effective, and scalable alternative to traditional batch processing. As the demand for biologics, including monoclonal antibodies, vaccines, and cell and gene therapies, continues to rise, the biopharmaceutical industry is under increasing pressure to optimize production processes while maintaining high product quality. Traditional batch processing, which involves stepwise production in separate phases, often leads to long cycle times, increased operational costs, and variability in product quality. In contrast, continuous bioprocessing enables real-time, uninterrupted production, allowing for greater consistency, higher yields, and reduced production time.

One of the main drivers behind the adoption of continuous bioprocessing is the growing focus on process intensification and operational efficiency. By integrating continuous upstream and downstream processing techniques, manufacturers can significantly reduce the footprint of biomanufacturing facilities, optimize resource utilization, and minimize waste generation. Furthermore, regulatory agencies such as the FDA and EMA are increasingly supporting the transition to continuous manufacturing due to its potential to enhance process control, improve scalability, and ensure robust product quality. As the industry moves toward personalized medicine and rapid vaccine development, continuous bioprocessing is emerging as a game-changing approach that accelerates drug production while maintaining stringent regulatory compliance.

How Are Technological Advancements Driving the Evolution of Continuous Bioprocessing?

Technological advancements are at the core of the rapid adoption of continuous bioprocessing, enabling greater automation, real-time monitoring, and enhanced process control. The integration of perfusion bioreactors, single-use technologies, and advanced chromatography systems has played a crucial role in making continuous processing a viable alternative to traditional batch methods. Perfusion bioreactors, in particular, allow for the constant renewal of culture media while maintaining cell viability and productivity, ensuring higher yields of biologics with reduced process interruptions.

The implementation of process analytical technology and real-time monitoring systems has further revolutionized continuous bioprocessing. Advanced sensor technologies, AI-driven data analytics, and digital twins are being utilized to continuously monitor critical process parameters, such as pH, dissolved oxygen, nutrient levels, and cell density. This real-time data collection enables predictive process control, early detection of deviations, and immediate corrective actions, reducing the risk of batch failures and product inconsistencies. Additionally, single-use bioprocessing systems are gaining traction in continuous manufacturing, allowing for greater flexibility, reduced contamination risks, and lower capital expenditures. With the increasing convergence of bioprocess automation, machine learning, and digital biomanufacturing, continuous processing is rapidly evolving into a fully integrated, highly efficient, and cost-effective production model.

What Are the Key Industry Applications of Continuous Bioprocessing?

Continuous bioprocessing is being widely adopted across multiple segments of the biopharmaceutical industry, where efficiency, scalability, and process reliability are paramount. One of the primary areas of application is in the manufacturing of monoclonal antibodies, where the ability to maintain a stable cell culture and continuously harvest high-quality biologics has significantly improved production efficiency. With the rising demand for targeted therapies and biosimilars, continuous processing is enabling biopharma companies to produce monoclonal antibodies at a lower cost while maintaining high purity and potency.

Another major application of continuous bioprocessing is in vaccine production, particularly with the growing need for rapid response platforms for pandemic preparedness. Traditional vaccine manufacturing often faces challenges related to scale-up limitations and long production cycles, but continuous processes allow for faster, more adaptable production that can meet emergency demands efficiently. Similarly, cell and gene therapy manufacturing is increasingly leveraging continuous bioprocessing approaches to enhance viral vector production, improve cell expansion techniques, and reduce time-to-market for personalized therapies. The biologics contract manufacturing sector is also witnessing a surge in demand for continuous production solutions, as companies seek to optimize large-scale biomanufacturing while ensuring compliance with evolving regulatory standards.

What Factors Are Driving Growth in the Continuous Bioprocessing Market?

The growth in the continuous bioprocessing market is driven by several factors, including the increasing global demand for biologics, advancements in bioprocessing technology, regulatory support for continuous manufacturing, and the need for cost-efficient production solutions. With the expansion of biosimilars and personalized medicine, pharmaceutical companies are under pressure to develop more flexible and scalable manufacturing processes that can accommodate varying production demands. Continuous bioprocessing enables manufacturers to achieve higher productivity, reduced cycle times, and lower operating costs, making it an attractive investment for biopharma companies seeking long-term process efficiency.

Another key driver is the growing adoption of Industry 4.0 technologies, including automation, AI-driven analytics, and real-time process control, which are enhancing the precision and reliability of continuous bioprocessing systems. The increasing focus on sustainable biomanufacturing is also playing a significant role, as continuous processing minimizes energy consumption, reduces waste generation, and improves overall resource utilization. Additionally, the biopharmaceutical industry’s shift toward modular and single-use bioprocessing facilities is accelerating the adoption of continuous manufacturing, providing companies with greater operational flexibility and cost savings. As the need for high-speed, high-efficiency biopharmaceutical production continues to grow, continuous bioprocessing is poised to become the future of biologics manufacturing, ensuring faster drug development, higher quality standards, and greater accessibility of life-saving therapies worldwide.

SCOPE OF STUDY:

The report analyzes the Continuous Bioprocessing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Bioprocessing Instruments, Bioprocessing Consumables); Scale of Operation (Commercial Operation, Research and Development Operation); Process Type (Downstream Bioprocess, Upstream Bioprocess); Application (Monoclonal Antibodies Application, Vaccines Application, Cell and Gene Therapy Application, Other Applications); End-Use (Pharmaceutical and Biotechnology Companies End-Use, CMOs and CROs End-Use, Research and Academic Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • 3M Company
  • AGC Biologics
  • Biogen Inc.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Corning Incorporated
  • Danaher Corporation
  • Entegris, Inc.
  • Enzene Biosciences Ltd.
  • Eppendorf SE
  • FUJIFILM Diosynth Biotechnologies
  • Meissner Filtration Products, Inc.
  • Merck KGaA
  • Novasep
  • Repligen Corporation
  • Sanofi Genzyme
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
  • UCB Pharma
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Continuous Bioprocessing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Biologics and Biosimilars Production Propels Adoption of Continuous Bioprocessing Platforms
    • Demand for Higher Throughput and Cost Efficiency Strengthens the Case for Transition from Batch to Continuous Systems
    • Smaller Facility Footprints and Modular Plant Design Accelerate Investment in Continuous Manufacturing
    • Growing Adoption in Monoclonal Antibody and Cell Therapy Production Expands Market Use Cases
    • Supportive Regulatory Guidance from FDA and EMA Enhances Confidence in Continuous Bioprocess Implementation
    • Advancements in Single-Use Technologies and Inline Monitoring Systems Drive Technical Feasibility
    • Demand for Real-Time Quality Control and Process Analytics Propels PAT Integration in Bioprocessing
    • Push for Scalability and Flexibility in Biopharma Manufacturing Supports Continuous Upstream and Downstream Adoption
    • Increased Pressure on CDMOs to Shorten Time-to-Market Fuels Adoption of Continuous Production Models
    • Greater Efficiency in Media Preparation and Feeding Systems Enhances Upstream Process Economics
    • Rising Use of Perfusion Bioreactors and Continuous Chromatography Drives Innovation in End-to-End Solutions
    • High Capital Costs and Technical Barriers Pose Challenges to Widespread Commercial Deployment
    • Cross-Functional Collaboration Between Equipment Vendors and Biomanufacturers Accelerates Process Optimization
    • Growing Focus on Personalized Medicine and Small Batch Sizes Favors Continuous and Flexible Production Models
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Continuous Bioprocessing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Continuous Bioprocessing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Continuous Bioprocessing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Continuous Bioprocessing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Bioprocessing Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Bioprocessing Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Bioprocessing Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Bioprocessing Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Bioprocessing Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Bioprocessing Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Monoclonal Antibodies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Monoclonal Antibodies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Monoclonal Antibodies Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Vaccines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cell & Gene Therapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cell & Gene Therapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Cell & Gene Therapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharmaceutical and Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pharmaceutical and Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Pharmaceutical and Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for CMOs & CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for CMOs & CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for CMOs & CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Research & Academic Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Research & Academic Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Commercial Operation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Commercial Operation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Commercial Operation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Research & Development Operation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Research & Development Operation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Research & Development Operation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Downstream Bioprocess by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Downstream Bioprocess by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Downstream Bioprocess by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Upstream Bioprocess by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Upstream Bioprocess by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Upstream Bioprocess by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Canada 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • JAPAN
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Japan 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Japan 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • CHINA
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 89: China Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 95: China Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: China 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: China 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: China 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • EUROPE
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Continuous Bioprocessing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Continuous Bioprocessing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Continuous Bioprocessing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Europe 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Europe 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Europe 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Europe 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • FRANCE
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 122: France Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: France 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: France 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 128: France Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: France 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: France 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 134: France Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: France Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: France 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • GERMANY
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Germany 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Germany 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Germany 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 146: Germany Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Germany Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Germany 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 149: Germany Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Germany Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Germany 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Italy 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Italy 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 158: Italy Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Italy Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Italy 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 161: Italy Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Italy Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Italy 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 164: Italy Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Italy Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Italy 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 167: UK Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: UK 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 170: UK Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: UK Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: UK 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 173: UK Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: UK Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: UK 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 176: UK Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: UK Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: UK 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 179: UK Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: UK Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: UK 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 182: Spain Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Spain Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Spain 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 185: Spain Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Spain Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Spain 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 188: Spain Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Spain Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Spain 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 191: Spain Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Spain Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Spain 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 194: Spain Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Spain Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Spain 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 197: Russia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Russia Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Russia 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 200: Russia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Russia Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Russia 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 203: Russia Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Russia Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Russia 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 206: Russia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Russia Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Russia 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 209: Russia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Russia Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Russia 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 212: Rest of Europe Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Rest of Europe Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Rest of Europe 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 215: Rest of Europe Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Europe Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Europe 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 218: Rest of Europe Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Rest of Europe Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Rest of Europe 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 221: Rest of Europe Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Rest of Europe Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Rest of Europe 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 224: Rest of Europe Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Europe Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Europe 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 227: Asia-Pacific Recent Past, Current & Future Analysis for Continuous Bioprocessing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 228: Asia-Pacific Historic Review for Continuous Bioprocessing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Asia-Pacific 15-Year Perspective for Continuous Bioprocessing by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 230: Asia-Pacific Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Asia-Pacific Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Asia-Pacific 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 233: Asia-Pacific Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Asia-Pacific Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Asia-Pacific 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 236: Asia-Pacific Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Asia-Pacific Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Asia-Pacific 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 239: Asia-Pacific Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Asia-Pacific Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Asia-Pacific 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Asia-Pacific Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Asia-Pacific 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 245: Australia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Australia Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Australia 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 248: Australia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Australia Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Australia 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 251: Australia Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Australia Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Australia 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 254: Australia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Australia Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Australia 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 257: Australia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Australia Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Australia 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • INDIA
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 260: India Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: India Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: India 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 263: India Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: India Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: India 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 266: India Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: India Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: India 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 269: India Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: India Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: India 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 272: India Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: India Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: India 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 275: South Korea Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: South Korea Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: South Korea 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 278: South Korea Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: South Korea Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: South Korea 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 281: South Korea Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: South Korea Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: South Korea 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 284: South Korea Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: South Korea Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: South Korea 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 287: South Korea Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: South Korea Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: South Korea 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 290: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Asia-Pacific Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Asia-Pacific 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Asia-Pacific Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Asia-Pacific 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Asia-Pacific Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Asia-Pacific 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Asia-Pacific Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Asia-Pacific 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Asia-Pacific Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Asia-Pacific 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 305: Latin America Recent Past, Current & Future Analysis for Continuous Bioprocessing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 306: Latin America Historic Review for Continuous Bioprocessing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Latin America 15-Year Perspective for Continuous Bioprocessing by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 308: Latin America Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Latin America Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Latin America 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 311: Latin America Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Latin America Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Latin America 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 314: Latin America Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Latin America Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Latin America 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 317: Latin America Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Latin America Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Latin America 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 320: Latin America Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Latin America Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 322: Latin America 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 323: Argentina Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Argentina Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 325: Argentina 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 326: Argentina Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Argentina Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 328: Argentina 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 329: Argentina Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Argentina Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 331: Argentina 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 332: Argentina Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Argentina Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 334: Argentina 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 335: Argentina Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Argentina Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 337: Argentina 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 338: Brazil Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Brazil Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 340: Brazil 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 341: Brazil Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Brazil Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 343: Brazil 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 344: Brazil Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Brazil Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 346: Brazil 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 347: Brazil Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Brazil Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 349: Brazil 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 350: Brazil Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Brazil Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 352: Brazil 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 353: Mexico Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Mexico Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 355: Mexico 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 356: Mexico Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Mexico Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 358: Mexico 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 359: Mexico Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Mexico Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 361: Mexico 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 362: Mexico Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Mexico Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 364: Mexico 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 365: Mexico Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Mexico Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 367: Mexico 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 368: Rest of Latin America Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Rest of Latin America Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 370: Rest of Latin America 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 371: Rest of Latin America Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Rest of Latin America Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 373: Rest of Latin America 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 374: Rest of Latin America Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Latin America Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Latin America 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Latin America Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Latin America Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Latin America 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 380: Rest of Latin America Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Rest of Latin America Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 382: Rest of Latin America 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 383: Middle East Recent Past, Current & Future Analysis for Continuous Bioprocessing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 384: Middle East Historic Review for Continuous Bioprocessing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 385: Middle East 15-Year Perspective for Continuous Bioprocessing by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 386: Middle East Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Middle East Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 388: Middle East 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 389: Middle East Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Middle East Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 391: Middle East 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 392: Middle East Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 393: Middle East Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 394: Middle East 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 395: Middle East Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Middle East Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 397: Middle East 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 398: Middle East Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Middle East Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 400: Middle East 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 401: Iran Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Iran Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 403: Iran 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 404: Iran Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Iran Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 406: Iran 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 407: Iran Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Iran Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 409: Iran 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 410: Iran Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Iran Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 412: Iran 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 413: Iran Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Iran Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 415: Iran 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 416: Israel Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Israel Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 418: Israel 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 419: Israel Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 420: Israel Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 421: Israel 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 422: Israel Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 423: Israel Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 424: Israel 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 425: Israel Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 426: Israel Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 427: Israel 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 428: Israel Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 429: Israel Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 430: Israel 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 431: Saudi Arabia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 432: Saudi Arabia Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 433: Saudi Arabia 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 434: Saudi Arabia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 435: Saudi Arabia Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 436: Saudi Arabia 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 437: Saudi Arabia Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 438: Saudi Arabia Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 439: Saudi Arabia 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 440: Saudi Arabia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 441: Saudi Arabia Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 442: Saudi Arabia 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 443: Saudi Arabia Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 444: Saudi Arabia Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 445: Saudi Arabia 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 446: UAE Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 447: UAE Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 448: UAE 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 449: UAE Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 450: UAE Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 451: UAE 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 452: UAE Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 453: UAE Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 454: UAE 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 455: UAE Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 456: UAE Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 457: UAE 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 458: UAE Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 459: UAE Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 460: UAE 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 461: Rest of Middle East Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 462: Rest of Middle East Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 463: Rest of Middle East 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 464: Rest of Middle East Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 465: Rest of Middle East Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 466: Rest of Middle East 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 467: Rest of Middle East Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 468: Rest of Middle East Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 469: Rest of Middle East 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 470: Rest of Middle East Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 471: Rest of Middle East Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 472: Rest of Middle East 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 473: Rest of Middle East Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 474: Rest of Middle East Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 475: Rest of Middle East 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030
  • AFRICA
    • Continuous Bioprocessing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 476: Africa Recent Past, Current & Future Analysis for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 477: Africa Historic Review for Continuous Bioprocessing by Product Type - Bioprocessing Instruments and Bioprocessing Consumables Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 478: Africa 15-Year Perspective for Continuous Bioprocessing by Product Type - Percentage Breakdown of Value Sales for Bioprocessing Instruments and Bioprocessing Consumables for the Years 2015, 2025 & 2030
    • TABLE 479: Africa Recent Past, Current & Future Analysis for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 480: Africa Historic Review for Continuous Bioprocessing by Application - Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 481: Africa 15-Year Perspective for Continuous Bioprocessing by Application - Percentage Breakdown of Value Sales for Other Applications, Monoclonal Antibodies Application, Vaccines Application and Cell & Gene Therapy Application for the Years 2015, 2025 & 2030
    • TABLE 482: Africa Recent Past, Current & Future Analysis for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 483: Africa Historic Review for Continuous Bioprocessing by End-Use - Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 484: Africa 15-Year Perspective for Continuous Bioprocessing by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology Companies End-Use, CMOs & CROs End-Use and Research & Academic Institutes End-Use for the Years 2015, 2025 & 2030
    • TABLE 485: Africa Recent Past, Current & Future Analysis for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 486: Africa Historic Review for Continuous Bioprocessing by Scale of Operation - Commercial Operation and Research & Development Operation Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 487: Africa 15-Year Perspective for Continuous Bioprocessing by Scale of Operation - Percentage Breakdown of Value Sales for Commercial Operation and Research & Development Operation for the Years 2015, 2025 & 2030
    • TABLE 488: Africa Recent Past, Current & Future Analysis for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 489: Africa Historic Review for Continuous Bioprocessing by Process Type - Downstream Bioprocess and Upstream Bioprocess Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 490: Africa 15-Year Perspective for Continuous Bioprocessing by Process Type - Percentage Breakdown of Value Sales for Downstream Bioprocess and Upstream Bioprocess for the Years 2015, 2025 & 2030

IV. COMPETITION